September 6, 2016 – Monona, WI – SHINE Medical Technologies, Inc. (SHINE), a Wisconsin-based company dedicated to being the world leader in the safe, clean, affordable production of medical isotopes, announced today that the company has been invited to speak at the 2016 Mo-99 Topical Meeting hosted by the Department of Energy’s Department of Energyn (DOE/NNSA).
Held in St. Louis, Missouri from September 11-14, the DOE/NNSA Mo‑99 Topical Meeting is a discussion forum for regulatory, policy and technical experts working toward a reliable global supply of molybdenum-99 (Mo-99) produced without the use of highly-enriched uranium. At the meeting, Katrina Pitas, Vice President of Business Development, will present an overview of SHINE’s groundbreaking Mo-99 production technology and provide an update on the status of the SHINE project.
Earlier this year, SHINE received approval from the Nuclear Regulatory Commission to begin construction on their radioisotope production facility in Janesville, Wisconsin, which will produce Mo-99 and other radioisotopes.
Molybdenum-99 (Mo-99) is a radioisotope that decays into the diagnostic imaging agent technetium‑99m (Tc-99m). Tc-99m is used in more than 40 million medical imaging procedures each year, primarily in stress tests to diagnose heart disease and bone scans to stage cancer. SHINE was founded to deploy a safe, cost-effective and environmentally friendly technology to produce medical isotopes, including Mo‑99.
About SHINE Medical Technologies, Inc.
Founded in 2010, SHINE is a development-stage company working toward becoming a manufacturer of radioisotopes for nuclear medicine. The SHINE system uses a patented, proprietary manufacturing process that offers major advantages over existing and proposed production technologies as it does not require a nuclear reactor, uses less electricity, generates less waste and is compatible with the nation’s existing supply chain for Mo-99. In 2014, SHINE announced the execution of Mo-99 supply agreements with GE Healthcare and Lantheus Medical Imaging. In 2015, with the help of Argonne National Laboratory, GE Healthcare demonstrated SHINE Mo-99 can act as a drop-in replacement for reactor-based Mo‑99. In June of 2016, SHINE signed a Mo-99 supply agreement with HTA Co., Ltd., the largest Chinese producer and distributor of radiopharmaceuticals.